<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Discovery of immunoproteasome inhibitors using large-scale covalent virtual screening</dc:title><dc:creator>Scarpino,	Andrea	(Avtor)
	</dc:creator><dc:creator>Bajusz,	Dávid	(Avtor)
	</dc:creator><dc:creator>Proj,	Matic	(Avtor)
	</dc:creator><dc:creator>Gobec,	Martina	(Avtor)
	</dc:creator><dc:creator>Sosič,	Izidor	(Avtor)
	</dc:creator><dc:creator>Gobec,	Stanislav	(Avtor)
	</dc:creator><dc:creator>Ferenczy,	György G.	(Avtor)
	</dc:creator><dc:creator>Keserü M.,	György	(Avtor)
	</dc:creator><dc:subject>immunoproteasome</dc:subject><dc:subject>covalent inhibitor</dc:subject><dc:subject>virtual screening</dc:subject><dc:subject>β5i selective inhibitor</dc:subject><dc:description>Large-scale virtual screening of boronic acid derivatives was performed to identify nonpeptidic covalent inhibitors of the β5i subunit of the immunoproteasome. A hierarchical virtual screening cascade including noncovalent and covalent docking steps was applied to a virtual library of over 104,000 compounds. Then, 32 virtual hits were selected, out of which five were experimentally confirmed. Biophysical and biochemical tests showed micromolar binding affinity and time-dependent inhibitory potency for two compounds. These results validate the computational protocol that allows the screening of large compound collections. One of the lead-like boronic acid derivatives identified as a covalent immunoproteasome inhibitor is a suitable starting point for chemical optimization.</dc:description><dc:date>2019</dc:date><dc:date>2021-11-04 13:40:57</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>132844</dc:identifier><dc:identifier>UDK: 615.4:54</dc:identifier><dc:identifier>ISSN pri članku: 1420-3049</dc:identifier><dc:identifier>DOI: 10.3390/molecules24142590</dc:identifier><dc:identifier>COBISS_ID: 4765297</dc:identifier><dc:language>sl</dc:language></metadata>
